Literature DB >> 20721843

[Diagnosis and treatment of gastric cancer].

F Lordick1, L Grenacher, C Röcken, M Ebert, M Moehler, G Schumacher.   

Abstract

From a global perspective, gastric cancer including cancer of the esophago-gastric junction is the fourth most common malignant tumor and the second-most common cause of cancer-related death. Due to the lack of screening programs in Western countries, most gastric cancers are diagnosed in advanced stages. A sophisticated staging should include high-resolution computed tomography of the thorax, abdomen and pelvis and video-documented endoscopy and endoscopic ultrasound. In mucosal gastric cancer, endoscopic resection can replace surgical resection if specific criteria are present. In the stages II and III perioperative chemotherapy has been established as a standard of care and should be applied. In the metastatic setting, treatment goals are palliative. Chemotherapy can prolong survival, improve symptoms and can help to maintain a better quality of life. Combination chemotherapy including a platinum compound and a fluoropyrimidine regarded as standard. About 20 % of gastric cancers exhibit overexpression of the growth factor receptor family member Her2. Trastuzumab is a monoclonal antibody directed against Her2 and has shown to prolong survival when combined with cisplatin and 5-fluorouracil or capecitabine. Georg Thieme Verlag KG Stuttgart-New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20721843     DOI: 10.1055/s-0030-1262460

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

Review 1.  [Gastric cancer and adenocarcinoma of the esophagogastric junction: principles of neoadjuvant therapy].

Authors:  F Lordick; K Ott; A Sendler
Journal:  Chirurg       Date:  2011-11       Impact factor: 0.955

2.  Prognostic relevance of gastric cancer staging by endoscopic ultrasound.

Authors:  Christian Jürgensen; Jana Brand; Michael Nothnagel; Alexander Arlt; Frank Neser; Jörg-Olaf Habeck; Stefan Schreiber; Ulrich Stölzel; Martin Zeitz; Jochen Hampe
Journal:  Surg Endosc       Date:  2012-10-06       Impact factor: 4.584

3.  Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort.

Authors:  Christoph Röcken; Hans-Michael Behrens; Christine Böger; Sandra Krüger
Journal:  J Clin Pathol       Date:  2015-08-06       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.